VivoSeq
Oncology

Uterine Sarcoma

10

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Uterine Sarcoma is an early-stage landscape with 10 programs across 8 companies. The most active players are Bristol-Myers Squibb, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Stemline Therapeutics, Inc.. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

33/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

Phase 2S

Stemline Therapeutics, Inc.

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

ApprovedPfizer logo

Pfizer

1 program

ApprovedNovartis logo

Novartis

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

6

clinical trials

Terminated2 · 33%
Unknown status1 · 17%
Completed1 · 17%
No longer available1 · 17%
Not yet recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Not yet recruiting·—·Phase 2·NCT07467772·30 enrolled
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT01979393·58 enrolled
Vorinostat (SAHA) in Uterine Sarcoma
Terminated·MMedical University of Graz·Phase 2·NCT03509207·3 enrolled
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
Terminated·—·N/A·NCT01958580·3 enrolled
The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas
Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00162721·270 enrolled
Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)
No longer available·TThe University of Texas Health Science Center at San Antonio·N/A·NCT03493165

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)